Shares of Gilead Sciences (NASDAQ:GILD) traded at a new 52-week high today of $41.61. So far today approximately 3.3 million shares have been exchanged, as compared to an average 30-day volume of 6.7 million shares.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

In the past 52 weeks, shares of Gilead Sciences have traded between a low of $21.91 and a high of $41.61 and are now at $41.45, which is 89% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.7% while the 50-day MA has advanced 0.5%.

Gilead Sciences (NASDAQ:GILD) has potential upside of 11.0% based on a current price of $41.45 and analysts' consensus price target of $46.00. The stock should find initial support at its 50-day moving average (MA) of $38.44 and further support at its 200-day MA of $31.66.

SmarTrend recommended that subscribers consider buying shares of Gilead Sciences on July 30th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $27.87. Since that recommendation, shares of Gilead Sciences have risen 48.5%. We continue to monitor GILD for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.